{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:45:48Z","timestamp":1793832348922,"version":"4.6.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Science and Technology","award":["MOST 108-2635-B-002-003"],"award-info":[{"award-number":["MOST 108-2635-B-002-003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Decisional conflict might occur during shared decision-making (SDM) because immunotherapy is a rather novel treatment option for patients with cancer. To explore the prevalence and severity of physical and psychological symptoms and the effort invested in SDM in relation to decisional conflict among patients with cancer undergoing immunotherapy combined with chemotherapy or targeted therapy. This was a cross-sectional survey study. The SURE version of the Decisional Conflict Scale was used to screen cancer patients\u2019 decisional conflict status. Demographic or clinical characteristics, physical symptoms and psychological distress; efforts invested in the SDM process were also assessed as potential factors related to decisional conflict. One hundred seventeen patients surveyed, the prevalence of fatigue (79.5%), sleep disturbance (78.6%), poor appetite (67.5%), and pain (58.1%) symptoms were high and the severity was at moderate levels. The prevalence of pruritus (40.2%), rash (34.2%), dry skin (41.9%), and diarrhea (17.1%) symptoms were low and the severity was at mild levels. 65.8% of patients reported uncertainty, with mild to moderate levels. Furthermore, 97.4% of the patients made some effort in SDM, and the effort level was moderate (mean: 5.56\u2009\u00b1\u20092.02). 64.1% of patients were certain that immunotherapy was the best option. Age, uncertainty, and effort in the SDM process were major factors related to decisional conflict. We observed that older patients (age:\u2009\u2265\u200965) and those with higher uncertainty levels and less effort in SDM reported higher levels of decisional conflict. Future studies should explore older patients\u2019 decisional related needs of immunotherapy. Interventions should be designed to reduce the uncertainty experienced by patients with cancer and enhance their understanding of immunotherapy to enable them to take more effort in the SDM process.<\/jats:p>","DOI":"10.1038\/s41598-023-39280-6","type":"journal-article","created":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T06:01:58Z","timestamp":1691215318000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Decisional conflict and its determinants among patients with cancer undergoing immunotherapy combined with chemotherapy or targeted therapy: a cross-sectional study"],"prefix":"10.1038","volume":"13","author":[{"given":"Yun-Hsiang","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yin","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeur-Hur","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Tai","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-Chi","family":"Hsaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Xuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,5]]},"reference":[{"key":"39280_CR1","unstructured":"World Health Organization. Cancer. https:\/\/www.who.int\/health-topics\/cancer#tab=tab_1. (2021)."},{"key":"39280_CR2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13046-019-1266-0","volume":"38","author":"S Kruger","year":"2019","unstructured":"Kruger, S. et al. Advances in cancer immunotherapy 2019-latest trends. J. Exp. Clin. Cancer Res. 38, 268. https:\/\/doi.org\/10.1186\/s13046-019-1266-0 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"39280_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","volume":"12","author":"A Akinleye","year":"2019","unstructured":"Akinleye, A. & Rasool, Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J. Hematol. Oncol. 12, 92. https:\/\/doi.org\/10.1186\/s13045-019-0779-5 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"39280_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3923\/pjbs.2018.135.150","volume":"21","author":"F Nouri Rouzbahani","year":"2018","unstructured":"Nouri Rouzbahani, F. et al. Immunotherapy a New Hope for cancer treatment: A review. Pak. J. Biol. Sci. 21, 135\u2013150. https:\/\/doi.org\/10.3923\/pjbs.2018.135.150 (2018).","journal-title":"Pak. J. Biol. Sci."},{"key":"39280_CR5","doi-asserted-by":"publisher","first-page":"e11936","DOI":"10.1097\/MD.0000000000011936","volume":"97","author":"M Khan","year":"2018","unstructured":"Khan, M. et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. Med. (Baltim) 97, e11936. https:\/\/doi.org\/10.1097\/MD.0000000000011936 (2018).","journal-title":"Med. (Baltim)"},{"key":"39280_CR6","doi-asserted-by":"publisher","first-page":"102984","DOI":"10.1016\/j.critrevonc.2020.102984","volume":"153","author":"A Lau","year":"2020","unstructured":"Lau, A., Yang, W. F., Li, K. Y. & Su, Y. X. Systemic therapy in recurrent or metastatic head and neck squamous cell carcinoma-A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 153, 102984. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102984 (2020).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"39280_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/annonc\/mdz003","volume":"30","author":"E Borcoman","year":"2019","unstructured":"Borcoman, E. et al. Novel patterns of response under immunotherapy. Ann. Oncol. 30, 385\u2013396. https:\/\/doi.org\/10.1093\/annonc\/mdz003 (2019).","journal-title":"Ann. Oncol."},{"key":"39280_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/0272989X08327067","volume":"29","author":"A LeBlanc","year":"2009","unstructured":"LeBlanc, A., Kenny, D. A., O\u2019Connor, A. M. & L\u00e9gar\u00e9, F. Decisional conflict in patients and their physicians: A dyadic approach to shared decision making. Med. Decis. Mak. 29, 61\u201368. https:\/\/doi.org\/10.1177\/0272989X08327067 (2009).","journal-title":"Med. Decis. Mak."},{"key":"39280_CR9","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi, L., Buqu\u00e9, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28, 690\u2013714. https:\/\/doi.org\/10.1016\/j.ccell.2015.10.012 (2015).","journal-title":"Cancer Cell"},{"key":"39280_CR10","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005 (2018).","journal-title":"N. Engl. J. Med."},{"key":"39280_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.smim.2016.01.001","volume":"28","author":"L Robert","year":"2016","unstructured":"Robert, L., Ribas, A. & Hu-Lieskovan, S. Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?. Semin. Immunol. 28, 73\u201380. https:\/\/doi.org\/10.1016\/j.smim.2016.01.001 (2016).","journal-title":"Semin. Immunol."},{"key":"39280_CR12","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand, U. et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 10, 1367\u20131401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007 (2023).","journal-title":"Genes Dis."},{"key":"39280_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","volume":"7","author":"P Xing","year":"2019","unstructured":"Xing, P. et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: A systematic review and meta-analysis. J. Immunother. Cancer 7, 341. https:\/\/doi.org\/10.1186\/s40425-019-0779-6 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"39280_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/00012272-199703000-00003","volume":"19","author":"ER Lenz","year":"1997","unstructured":"Lenz, E. R., Pugh, L. C., Milligan, R. A., Gift, A. & Suppe, F. The middle-range theory of unpleasant symptoms: An update. ANS Adv. Nurs. Sci. 19, 14\u201327. https:\/\/doi.org\/10.1097\/00012272-199703000-00003 (1997).","journal-title":"ANS Adv. Nurs. Sci."},{"key":"39280_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4103\/apjon.apjon_32_18","volume":"5","author":"JM Kates","year":"2018","unstructured":"Kates, J. M. Treatment-related decisional conflict, quality of life, and comorbidity in older adults with cancer. Asia Pac. J. Oncol. Nurs. 5, 421\u2013429. https:\/\/doi.org\/10.4103\/apjon.apjon_32_18 (2018).","journal-title":"Asia Pac. J. Oncol. Nurs."},{"key":"39280_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1037\/a0015205","volume":"28","author":"C Rini","year":"2009","unstructured":"Rini, C. et al. Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer patients who receive uninformative BRCA1\/2 results. Health Psychol. 28, 569\u2013578. https:\/\/doi.org\/10.1037\/a0015205 (2009).","journal-title":"Health Psychol."},{"key":"39280_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.21873\/anticanres.13107","volume":"39","author":"K Kokkonen","year":"2019","unstructured":"Kokkonen, K. et al. Cancer patients\u2019 symptom burden and health-related quality of life (HRQoL) at tertiary cancer center from 2006 to 2013: A cross-sectional study. Anticancer. Res. 39, 271\u2013277. https:\/\/doi.org\/10.21873\/anticanres.13107 (2019).","journal-title":"Anticancer. Res."},{"key":"39280_CR18","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00520-018-4443-3","volume":"27","author":"D Levy","year":"2019","unstructured":"Levy, D. et al. Certainty within uncertainty: A qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Support Care Cancer 27, 1845\u20131852. https:\/\/doi.org\/10.1007\/s00520-018-4443-3 (2019).","journal-title":"Support Care Cancer"},{"key":"39280_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1547-5069.1988.tb00082.x","volume":"20","author":"MH Mishel","year":"1988","unstructured":"Mishel, M. H. Uncertainty in illness. Image J. Nurs. Sch. 20, 225\u2013232. https:\/\/doi.org\/10.1111\/j.1547-5069.1988.tb00082.x (1988).","journal-title":"Image J. Nurs. Sch."},{"key":"39280_CR20","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3758\/s13421-015-0527-1","volume":"43","author":"MV Coutinho","year":"2015","unstructured":"Coutinho, M. V. et al. The interplay between uncertainty monitoring and working memory: Can metacognition become automatic?. Mem. Cognit. 43, 990\u20131006. https:\/\/doi.org\/10.3758\/s13421-015-0527-1 (2015).","journal-title":"Mem. Cognit."},{"key":"39280_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1188\/17.CJON.113-115","volume":"21","author":"A Gustafson","year":"2017","unstructured":"Gustafson, A. Reducing patient uncertainty: implementation of a shared decision-making process enhances treatment quality and provider communication. Clin. J. Oncol. Nurs. 21, 113\u2013115. https:\/\/doi.org\/10.1188\/17.CJON.113-115 (2017).","journal-title":"Clin. J. Oncol. Nurs."},{"key":"39280_CR22","doi-asserted-by":"publisher","first-page":"c5146","DOI":"10.1136\/bmj.c5146","volume":"341","author":"G Elwyn","year":"2010","unstructured":"Elwyn, G. et al. Implementing shared decision making in the NHS. BMJ 341, c5146. https:\/\/doi.org\/10.1136\/bmj.c5146 (2010).","journal-title":"BMJ"},{"key":"39280_CR23","unstructured":"Committee on improving the quality of cancer care: Addressing the challenges of an aging, P., S. Board on Health Care, and M. Institute of, in Delivering high-quality cancer care: charting a new course for a system in crisis, (eds Levit, L.) (National Academies Press, 2013). All rights reserved: Washington (DC). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK202153\/."},{"key":"39280_CR24","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s13187-020-01867-2","volume":"37","author":"A Ihrig","year":"2022","unstructured":"Ihrig, A. et al. The treatment decision-making preferences of patients with prostate cancer should be recorded in research and clinical routine: A pooled analysis of four survey studies with 7169 patients. J. Cancer Educ. 37, 675\u2013682. https:\/\/doi.org\/10.1007\/s13187-020-01867-2 (2022).","journal-title":"J. Cancer Educ."},{"key":"39280_CR25","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1200\/JCO.2002.20.6.1473","volume":"20","author":"NL Keating","year":"2002","unstructured":"Keating, N. L., Guadagnoli, E., Landrum, M. B., Borbas, C. & Weeks, J. C. Treatment decision making in early-stage breast cancer: should surgeons match patients\u2019 desired level of involvement?. J. Clin. Oncol. 20, 1473\u20131479. https:\/\/doi.org\/10.1200\/JCO.2002.20.6.1473 (2002).","journal-title":"J. Clin. Oncol."},{"key":"39280_CR26","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/pon.3835","volume":"24","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. The willingness and actual situation of Chinese cancer patients and their family members participating in medical decision-making. Psychooncology 24, 1663\u20131669. https:\/\/doi.org\/10.1002\/pon.3835 (2015).","journal-title":"Psychooncology"},{"key":"39280_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/pon.1590","volume":"19","author":"TF Hack","year":"2010","unstructured":"Hack, T. F. et al. Predictors of distress and quality of life in patients undergoing cancer therapy: Impact of treatment type and decisional role. Psycho. Oncol. 19, 606\u2013616. https:\/\/doi.org\/10.1002\/pon.1590 (2010).","journal-title":"Psycho. Oncol."},{"key":"39280_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1146\/annurev-psych-010419-050747","volume":"71","author":"B Fischhoff","year":"2020","unstructured":"Fischhoff, B. & Broomell, S. B. Judgment and decision making. Annu. Rev. Psychol. 71, 331\u2013355. https:\/\/doi.org\/10.1146\/annurev-psych-010419-050747 (2020).","journal-title":"Annu. Rev. Psychol."},{"key":"39280_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40463-018-0297-4","volume":"47","author":"ME Graham","year":"2018","unstructured":"Graham, M. E. et al. Shared decision making and decisional conflict in the management of vestibular schwannoma: A prospective cohort study. J. Otolaryngol. Head Neck Surg. 47, 52. https:\/\/doi.org\/10.1186\/s40463-018-0297-4 (2018).","journal-title":"J. Otolaryngol. Head Neck Surg."},{"issue":"5","key":"39280_CR30","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3978\/j.issn.2218-6751.2015.06.06","volume":"4","author":"J Villadolid","year":"2015","unstructured":"Villadolid, J. & Amin, A. Immune checkpoint inhibitors in clinical practice: Update on management of immune-related toxicities. Transl. Lung Cancer Res. 4(5), 560. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2015.06.06 (2015).","journal-title":"Transl. Lung Cancer Res."},{"key":"39280_CR31","first-page":"e308","volume":"56","author":"F L\u00e9gar\u00e9","year":"2010","unstructured":"L\u00e9gar\u00e9, F. et al. Are you SURE?: Assessing patient decisional conflict with a 4-item screening test. Can. Fam. Physician 56, e308\u2013e314 (2010).","journal-title":"Can. Fam. Physician"},{"key":"39280_CR32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1177\/0272989X13491463","volume":"34","author":"A Ferron Parayre","year":"2014","unstructured":"Ferron Parayre, A., Labrecque, M., Rousseau, M., Turcotte, S. & L\u00e9gar\u00e9, F. Validation of SURE, a four-item clinical checklist for detecting decisional conflict in patients. Med. Decis. Mak. 34, 54\u201362. https:\/\/doi.org\/10.1177\/0272989X13491463 (2014).","journal-title":"Med. Decis. Mak."},{"key":"39280_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/acprof:oso\/9780199231881.001.0001","volume-title":"Health measurement scales: A practical guide to their development and use","author":"DL Streiner","year":"2008","unstructured":"Streiner, D. L. & Norman, G. R. Health measurement scales: A practical guide to their development and use 4th edn. (Oxford University Press, 2008).","edition":"4"},{"key":"39280_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s41687-018-0056-3","volume":"2","author":"K Gries","year":"2017","unstructured":"Gries, K. et al. Literature review to assemble the evidence for response scales used in patient-reported outcome measures. J. Patient Rep. Outcomes 2, 41. https:\/\/doi.org\/10.1186\/s41687-018-0056-3 (2017).","journal-title":"J. Patient Rep. Outcomes"},{"key":"39280_CR35","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.2196\/jmir.3085","volume":"16","author":"PJ Barr","year":"2014","unstructured":"Barr, P. J. et al. The psychometric properties of CollaboRATE: A fast and frugal patient-reported measure of the shared decision-making process. J. Med. Internet Res. 16, e2. https:\/\/doi.org\/10.2196\/jmir.3085 (2014).","journal-title":"J. Med. Internet Res."},{"key":"39280_CR36","doi-asserted-by":"publisher","unstructured":"Orimo, H. [Reviewing the definition of elderly]. Nihon Ronen Igakkai Zasshi 43, 27\u201334 (2006). https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1111\/j.1447-0594.2006.00341.x.","DOI":"10.1111\/j.1447-0594.2006.00341.x"},{"key":"39280_CR37","unstructured":"Dictionary, C. Meaning of higher education. https:\/\/dictionary.cambridge.org\/dictionary\/english\/higher-education (2022)."},{"key":"39280_CR38","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken, M. M. et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am. J. Clin. Oncol. 5, 649\u2013655. https:\/\/doi.org\/10.1097\/00000421-198212000-00014 (1982).","journal-title":"Am. J. Clin. Oncol."},{"key":"39280_CR39","volume-title":"Logistic regression. Statistics for biology and health. Ordinal logistic regression","author":"DG Kleinbaum","year":"2010","unstructured":"Kleinbaum, D. G. & Klein, M. Logistic regression. Statistics for biology and health. Ordinal logistic regression (Springer, 2010)."},{"key":"39280_CR40","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.1200\/JCO.2006.07.1159","volume":"24","author":"J Mandelblatt","year":"2006","unstructured":"Mandelblatt, J., Kreling, B., Figeuriedo, M. & Feng, S. What is the impact of shared decision making on treatment and outcomes for older women with breast cancer?. J. Clin. Oncol. 24, 4908\u20134913. https:\/\/doi.org\/10.1200\/JCO.2006.07.1159 (2006).","journal-title":"J. Clin. Oncol."},{"key":"39280_CR41","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/(sici)1097-0258(19980730)17:14<1623::aid-sim871>3.0.co;2-s","volume":"17","author":"FY Hsieh","year":"1998","unstructured":"Hsieh, F. Y., Bloch, D. A. & Larsen, M. D. A simple method of sample size calculation for linear and logistic regression. Stat. Med. 17, 1623\u20131634. https:\/\/doi.org\/10.1002\/(sici)1097-0258(19980730)17:14%3c1623::aid-sim871%3e3.0.co;2-s (1998).","journal-title":"Stat. Med."},{"key":"39280_CR42","doi-asserted-by":"publisher","DOI":"10.1097\/ncc.0000000000001147","author":"CC Yu","year":"2022","unstructured":"Yu, C. C. et al. Reaffirming adverse events related to lung cancer survivors\u2019 target therapies and their apparent effects on fear of cancer progression, anxiety, and depression. Cancer Nurs. https:\/\/doi.org\/10.1097\/ncc.0000000000001147 (2022).","journal-title":"Cancer Nurs."},{"key":"39280_CR43","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.critrevonc.2013.11.008","volume":"90","author":"MA Pessi","year":"2014","unstructured":"Pessi, M. A. et al. Targeted therapy-induced diarrhea: A review of the literature. Crit. Rev. Oncol. Hematol. 90, 165\u2013179. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.11.008 (2014).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"39280_CR44","unstructured":"ASCO. Skin reactions to targeted therapy and immunotherapy. (Accessed 24 March 2022). https:\/\/www.cancer.net\/coping-with-cancer\/physical-emotional-and-social-effects-cancer\/managing-physical-side-effects\/skin-reactions-targeted-therapy-and-immunotherapy (2022)."},{"key":"39280_CR45","unstructured":"ASCO. Diarrhea. (Accessed 24 March 2022). https:\/\/www.cancer.net\/coping-with-cancer\/physical-emotional-and-social-effects-cancer\/managing-physical-side-effects\/diarrhea (2022)."},{"key":"39280_CR46","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440 (2021).","journal-title":"J. Clin. Oncol."},{"key":"39280_CR47","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0304-3959(94)00178-H","volume":"61","author":"RC Serlin","year":"1995","unstructured":"Serlin, R. C., Mendoza, T. R., Nakamura, Y., Edwards, K. R. & Cleeland, C. S. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61, 277\u2013284. https:\/\/doi.org\/10.1016\/0304-3959(94)00178-H (1995).","journal-title":"Pain"},{"key":"39280_CR48","unstructured":"American Psychological Association. Older adults\u2019 health and age-related changes. Accessed 22 Jun 2022 (2022)."},{"key":"39280_CR49","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000485247","volume":"64","author":"CE L\u00f6ckenhoff","year":"2018","unstructured":"L\u00f6ckenhoff, C. E. Aging and decision-making: A conceptual framework for future research-a mini-review. Gerontology 64, 140\u2013148. https:\/\/doi.org\/10.1159\/000485247 (2018).","journal-title":"Gerontology"},{"key":"39280_CR50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1369-7625.2010.00626.x","volume":"14","author":"MC Politi","year":"2011","unstructured":"Politi, M. C., Clark, M. A., Ombao, H., Dizon, D. & Elwyn, G. Communicating uncertainty can lead to less decision satisfaction: a necessary cost of involving patients in shared decision making?. Health Expect. 14, 84\u201391. https:\/\/doi.org\/10.1111\/j.1369-7625.2010.00626.x (2011).","journal-title":"Health Expect."},{"key":"39280_CR51","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1136\/pmj.78.920.319","volume":"78","author":"AF West","year":"2002","unstructured":"West, A. F. & West, R. R. Clinical decision-making: Coping with uncertainty. Postgrad. Med. J. 78, 319\u2013321. https:\/\/doi.org\/10.1136\/pmj.78.920.319 (2002).","journal-title":"Postgrad. Med. J."},{"key":"39280_CR52","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1188\/20.ONF.498-511","volume":"47","author":"KL Kwekkeboom","year":"2020","unstructured":"Kwekkeboom, K. L., Wieben, A., Stevens, J., Tostrud, L. & Montgomery, K. Guideline-recommended symptom management strategies that cross over two or more cancer symptoms. Oncol. Nurs. Forum 47, 498\u2013511. https:\/\/doi.org\/10.1188\/20.ONF.498-511 (2020).","journal-title":"Oncol. Nurs. Forum"},{"issue":"6","key":"39280_CR53","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/01.JAA.0000735760.65235.3c","volume":"34","author":"JJ Park","year":"2021","unstructured":"Park, J. J., Arafath, S., Kumar, S. T., Sharma, R. & Dixit, D. Managing toxicities associated with immune checkpoint inhibitors. JAAPA 34(6), 32\u201339. https:\/\/doi.org\/10.1097\/01.JAA.0000735760.65235.3c (2021).","journal-title":"JAAPA"},{"key":"39280_CR54","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2174\/1574887115666200622161418","volume":"15","author":"M Brigida","year":"2020","unstructured":"Brigida, M. et al. Management of Immunotherapy adverse events in oncological patients: Anti-CTLA-4, Anti-PD-1\/PD-L1. Rev. Recent Clin. Trials 15, 339\u2013346. https:\/\/doi.org\/10.2174\/1574887115666200622161418 (2020).","journal-title":"Rev. Recent Clin. Trials"},{"key":"39280_CR55","doi-asserted-by":"publisher","unstructured":"Grimm, P. Social desirability bias. Wiley international encyclopedia of marketing (2010).https:\/\/doi.org\/10.1002\/9781444316568.wiem02057","DOI":"10.1002\/9781444316568.wiem02057"},{"issue":"18","key":"39280_CR56","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1002\/sim.2737","volume":"26","author":"H Chen","year":"2007","unstructured":"Chen, H., Cohen, P. & Chen, S. Biased odds ratios from dichotomization of age. Stat. Med. 26(18), 3487\u20133497. https:\/\/doi.org\/10.1002\/sim.2737 (2007).","journal-title":"Stat. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39280-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39280-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39280-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T10:09:04Z","timestamp":1700388544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39280-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,5]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["39280"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-39280-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,5]]},"assertion":[{"value":"31 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12715"}}